Journal of Mental Science (1958) 104: 1056-1061. doi: 10.1192/bjp.104.437.1056
© 1958 The Royal College of Psychiatrists
Treatment of Anxiety States
II.—Clinical Trial of Benactyzine in Anxiety States
G. R. Hargreaves, O.B.E., M.Sc., M.R.C.S., Nuffield Professor of Psychiatry
Max Hamilton, M.D., D.P.M., Senior Research Fellow
Julian M. Roberts, M.B., Ch.B., D.P.M., Lecturer
Leeds University Department of Psychiatry, the General Infirmary at Leeds
ABSTRACT
- A clinical trial of benactyzine in anxiety states is described. All patients received simple psychotherapy, and in addition 14 received benactyzine and 12 were given blank tablets.
- The patient's condition at the start and end of the trial was measured with a rating scale with items dealing with specific symptoms. Although greater improvement occurred in the patients given drug compared with those given placebo in 11 out of 13 items, in only one did it reach a level of statistical significance.
- The use of two raters at the same interview provided evidence that knowledge of side effects did not influence ratings.
- The amount of improvement is not related to the length of illness, the previous personality, the presence of precipitating factors or family history of mental illness.
- The analysis of results was made complicated by a high correlation between original scores and amount of improvement, and by the use of three pairs of raters in the trial. This was dealt with by analysis of covariance.
Copyright © 1958 The Royal College of Psychiatrists.